NXI Therapeutics appoints Dr. Ruben Herrendorff as CEO and announced Dr. Ulf Grawunder joining its Board of Directors

– SWITZERLAND, Basel –  NXI Therapeutics, the biotech developing next-generation immunosuppressive drugs for autoimmune diseases and organ transplantation, today announced the appointment of Dr. Ruben Herrendorff (Ph.D.) as CEO and announced Dr. Ulf Grawunder (Ph.D.) is joining its Board of Directors.

“Joining NXI Therapeutics is a unique opportunity to support the company to realize these truly transformative therapies for patients affected by autoimmune diseases or those requiring organ/stem cell transplants. I am highly impressed by the underlying biology, the vast medical potential, and the clearly differentiated safety profile of this new therapeutic approach. We have a once-in-a-lifetime opportunity to develop and introduce the next generation of safe immunotherapies with broad applicability.” said CEO, Dr Ruben Herrendorff.

About Dr. Ruben Herrendorff

Dr. Ruben Herrendorff was previously co-founder and CEO of Polyneuron Pharmaceuticals AG, a blue-chip VC-backed biotech developing a new antigen-specific technology platform to tackle antibody-mediated autoimmune diseases.
About Dr. Ulf Grawunder
Dr. Grawunder is a successful serial biotech entrepreneur, who has founded and exited two biotech companies since 2004: 4-Antibody (sold to US-based Agenus) and NBE-Therapeutics (sold to Boehringer Ingelheim). Recently, Ulf became a Managing Partner at Swiss Viopas Venture Consulting and has co-founded T-CURX, which is focused on developing next-generation CAR-T cell therapies for cancer patients, where he has recently assumed the position of CEO.
Dr. Ulf Grawunder said: “I am deeply impressed by the depth and quality of the science underlying NXI Therapeutics’ approach to developing novel drug candidates that address unmet needs in autoimmunity and inflammation. Ruben has extensive business experience in building innovation-driven biotech enterprises and Rajesh is an outstanding clinician to drive the clinical translation of NXI Therapeutics’s drug assets. I am highly dedicated to supporting the management to bring new and transformative drugs to the market and patients.”
About NXI Therapeutics
NXI Therapeutics was founded in 2021 and is a privately-held biotech, spun out of the Biozentrum, the University of Basel, which is developing a novel revolutionary class of allo- and auto-immune selective immunosuppressants. NXI Therapeutics focuses on novel therapeutic modalities for autoimmune diseases and pathologic immune activation following organ/stem cell transplantation, where suppression of the immune system is required. The majority of current treatments lead to a generalized defective immune response due to over-suppression of the immune function. This can cause susceptibility to opportunistic infections, invasive cancers, and numerous side effects, thereby severely affecting patient survival and quality of life.
NXI Therapeutics is developing modulators of the coronin 1 signaling pathway to induce highly selective immunosuppression without affecting broader defenses against infectious diseases. This represents a major clinical improvement in the management of autoimmune conditions and complications following organ transplantation.
NXI Therapeutics’ therapeutic approach is derived from over 15 years of research conducted by co-founder Rajesh Jayachandran, M.D. Ph.D.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.